The round was led by new investors Innvierte, part of the Spanish Ministry of Science and Innovation (CDTI), and an undisclosed strategic investor, as well as participation from existing investors Kur...
Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company
Mediktor has announced that it has raised a €11 million financing round to keep on improving their elaborate technology and expand their international presence. The round was led by European healtht...
The financing round is led by Alta Life Sciences Spain I FCR, a vehicle managed by Altamar Private Equity SGIIC. Existing investors including Institut Català de Finances (ICF) have also participated ...
Peptomyc is relying on a strong syndicate of life sciences investors. This investment was led by AurorA Science and substantially supported by existing investors including Alta Life Sciences, HealthEq...
Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million Series A financing, with the par...
La ronda ha sido liderada por el fondo Sabadell-Asabys, gestionado por la firma Asabys Partners, y Alta Life Sciences Spain I, a la que se han unido otros inversores como el Institut Català de Financ...
The funding round was led by Alta Life Sciences and supported by the Centre for Technological and Industrial Development (CDTI). The company will develop a portfolio of new drug candidates to treat CN...
Mediktor arrancó con 1,6 millones de business angels locales, y ahora acaba de cerrar su primera ronda de serie A: 3 millones de euros, liderada por Alta Life Sciences. También participan en la rond...
Alta Life Sciences is leading a Series A round of 4 million euros to finance the clinical development of the BN201 for AON and NMO, that affects 130,000 patien ts a year only in United States and Euro...
La inversión ha sido liderada por Alta Life Sciences Spain I FCR e incluye a los actuales inversores Healthequity así como a “business angels” que participaron en la primera ronda de inversión ...
El fondo aspira a captar más de 100 millones de euros y a ser el mayor vehículo inversor en ciencias de la vida creado en España. El fondo estará gestionado por Altamar Capital Partners